1 / 47

Research in Neurosciences, A European Perspective

Research in Neurosciences, A European Perspective. Peter Paul De Deyn Scientific Director Institute Born-Bunge. The Network of European Neuroscience Schools.

deepak
Télécharger la présentation

Research in Neurosciences, A European Perspective

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Research in Neurosciences, A European Perspective Peter Paul De Deyn Scientific Director Institute Born-Bunge

  2. The Network of EuropeanNeuroscience Schools The Network of European Neuroscience Schools (NENS) was founded in 2003 and represents over 150 of those graduate schools and programmes across ca. 30 European countries that offer Masters, MD, PhD and doctoral degrees in neuroscience. NENS is a formal structure within the Federation of European Neuroscience Societies (FENS).

  3. The Network of EuropeanNeuroscience Schools The Network of European Neuroscience Schools (NENS) was founded in 2003 and represents over 150 of those graduate schools and programmes across ca. 30 European countries that offer Masters, MD, PhD and doctoral degrees in neuroscience. NENS is a formal structure within the Federation of European Neuroscience Societies (FENS).

  4. European Neuroscience and Society Network European network for interdisciplinary discussions of the social implications of the neurosciences. Funded by the European Science Foundation

  5. The Network of EuropeanNeuroscience Schools The Network of European Neuroscience Schools (NENS) was founded in 2003 and represents over 150 of those graduate schools and programmes across ca. 30 European countries that offer Masters, MD, PhD and doctoral degrees in neuroscience. NENS is a formal structure within the Federation of European Neuroscience Societies (FENS).

  6. The Network of EuropeanNeuroscience Schools

  7. Publication Analysis 1997-2008 Clinical Neurosciences

  8. European Commission – Health Research - Brain Research The strategic guidance for our funding of brain research is the 7th Framework Programme on Research and Technical Development (FP7) implemented through so-called Specific Programmes (SPs). Health research in general and brain research in particular is implemented in the Specific Programme Cooperation. Support for infrastructures is provided through the Specific Programme Capacities. The well-established Marie-Curie fellowships are funded through the Specific Programme People and the European Research Council is funded through the Specific Programme Ideas.

  9. European Commission – Health Research - Brain Research Brain research is supported in the Seventh Framework Programme (FP7; 2007-2013), which includes an activity on ‘Research on the brain and related diseases’ under the theme ‘Health’. This activity has a particular emphasis on translational research, meaning translation of basic discoveries into clinical applications. In the first three FP7 calls, 30 projects were funded under this activity for a total of EUR 135 million. Research relevant to the brain and the nervous system is also addressed in other areas of the current ‘Health’ theme, where an additional 49 research projects received funding for about EUR 247 million.

  10. Promoting Breakthrough Therapies across Europe Michel Goldman, MD,PhD Executive Director Belgian Brain Congress 2010

  11. Innovative Medicines Initiative:the Largest PPP in Life Sciences R&D 2 Billion Euro 1 Billion € 1 Billion € Public Private Partnership

  12. IMI: Topics for the First Call • Improved predictivity of immunogenicity 13m/ 5y • Non-genotoxic carcinogenesis 2.5m/2y plus 10m/ 3y • Expert systems for in silico toxicity prediction 5m/ 5y • Improved predictivity of non-clinical safety evaluation 10m/ 3y • Qualification of Translational safety biomarkers 21m/ 5y • Strengthening the monitoring of benefit/risk 15m/ 5y • Islet cell research 10m/ 5y • Surrogate markers for vascular endpoints 20m/ 5y • Pain research 7.5m/ 5y • New tools to develop novel therapies in psychiatric disorders 10m/ 5y • Neurodegenerative disorders 7.5m/ 5y • Understanding severe asthma 12.5m/ 5y • COPD Patient Reported Outcomes 2m/ 1y + 8m/5y • European Medicines Research Training Network 5m/ 7y • Safety sciences for medicines training programme 3m/ 5y • Pharmaceutical medicine training programme 4m/ 5y • Integrated medicines development training programme 3m/ 5y • Pharmacovigilance training programme 3.5m/ 5y EFPIA Commitment: 172.5m Euros, typical project ~15m, 5-10 EFPIA partners/project, majority of 5y duration

  13. IMI: Neurodegenerative Disorders Bridging the preclinical /clinical Clinical outcome studies in the neurodegeneration area are notoriously long and expensive. In order to accelerate the successful development of molecules for the treatment of Neurodegenerative disorders, it is essential to improve the predictive value of animal models, identify pharmacodynamic markers of drug response, pharmacodynamic models that allow early prediction of efficacy and markers to aid stratification of the patient population. The success of this will be dependent on the partnership of preclinical and clinical scientists to adopt an integrated approach to ensure effective translation of efficacy from bench to bedside and visa versa. This translational science/medicine approach will allow the rapid identification and accelerated development of successful candidate molecules as well as terminating efforts earlier on those unlikely to offer clinical benefit.

  14. IMI Projects on Brain Disorders • Alzheimer’s disease • Pilot project: Addneuromed • Ongoing project: Pharmacog (total budget: 27.7 M €) • Schizophrenia and depression • Ongoing project: Newmeds (total budget: 24.0 M €) • Autism • Call for Proposals to be released end October 2010

  15. Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development. PHARMA-COG

  16. Area 4.2 - Support to policies Description and scope of topic 4.2-8: HEALTH-2010.4.2-8: Coordination action in support of the implementation by participating States of a Joint Programming Initiative for combating neurodegenerative diseases, in particular Alzheimer's disease. Following the Commission's Communication on Joint Programming to tackle Europe's major societal challenges, the Competitiveness Council, called for a common commitment of EU Member States (MS) to fight Alzheimer's disease and other neurodegenerative diseases. The successful coordination action must support the implementation of a pilot Joint Programming Initiative by proposing innovative ways of pooling national expertise and resources and establishing closer and robust collaborations among the participating States in the field of neurodegenerative diseases, in particular Alzheimer's disease. Applicants must be national/regional agencies and/or ministries funding activities related to neurodegenerative diseases. Funding scheme: Coordination and Support Action (Coordinating Action).

  17. The European Brain Council (EBC), established in 2002, involves all major European organizations involved in brain-related issues ranging from scientific and clinical societies, to industry and patients organizations. EBC - together with its member organizations – promotes brain research in Europe; this will lead to new therapeutic and diagnostic tools and together with improved education and information. An important goal is to improve the quality of life of those European citizens living with brain-related diseases as well as of their carers.

  18. I: Development, plasticity & ageing of the brain in health & disease II. Mind – brain relationship and mental disorders III. Degeneration & repair in the Brain IV. Revealing pain mechanisms & their control V. Rehabilitation, psychological care & prevention VI. Sensory systems & autonomic disturbances VII. Towards a better diagnostic & therapeutic approach: enabling technologies

  19. Vision UA SOCIO ECO NANO NEURO VAXINFECTIO

  20. Institute Born-Bunge • Institute Bunge (clinic and research) : 1934-1962-1979 • “.. In order to establish a center for surgical and medical research where full diagnostic research could be combined with scientific research.” • Travaux de l’Institut Bunge Vol I, 1936. • Born-Bunge Foundation (research) : 1963-2004 • Institute Born-Bunge (research) : from 2005

  21. Ludo van Bogaert and Charles Poser 1955

  22. Prof. Armand Lowenthal1919-2001Intrathecal IgG synthesis in MS Micro-Eletrophoresis in Agar Gel of Proteins of the Cerebrospinal Fluid and Central Nervous System 1959. D. Karcher, M. van Sande and A. Lowenthal. Institute of Tropical Medicine, Antwerp, and Institute Bunge, Berchem Antwerp, Belgium Journal of Biochemistry 1959; 4: 135-140

  23. Prof. Armand Lowenthal

  24. Prof. J.J. Martin • Neurometabolic storage diseases (together with Prof. Ceuterick-De Groote) • Neuromuscular disorders • Detailed anatomical study of the thalamus • Neuropathological study of dementia

  25. Brief presentation IBB Laboratories and groups

  26. Laboratory for Electrobiology

  27. Laboratory for Neurobiology

  28. Laboratory for Theoretical Neurobiology

  29. Laboratory for Neurochemistry & Behaviour

  30. Laboratory for Neurochemistry & Behaviour

  31. Laboratory for Neurochemistry & Behaviour Reference for Biological Markers of Memory disorders

  32. LNG: Behavioural research and pharmacological modulation in rodent models of dementia Van Dam D. & De Deyn P.P. Drug development in dementia: the role of rodent models. Nature Reviews Drug Discovery (2006)

  33. IBB- Laboratories for Neurogenetics • Three research groups active in the investigation of complex neurological diseases of the peripheral and central nervous system • Peripheral Neuropathies • Vincent Timmerman • Neurogenetics • Peter De Jonghe • Neurodegenerative Brain diseases • Christine Van Broeckhoven

  34. Peripheral Neuropathy group About nerves, pedigrees and genes

  35. Neurogenetics group

  36. IBB- Neurodegenerative Brain diseases Group

  37. Frontotemporal Dementia with Ubiquitin-positive inclusions IBB- Neurodegenerative Brain diseases Group Key publications • Cruts,M., Gijselinck,I., van der Zee,J., Engelborghs,S., Wils,H., Pirici,D., Rademakers, R., Vandenberghe,R., Dermaut,B.,Martin,J-J., van Duijn,C., Peeters,K., Sciot,R., Santens,P., De Pooter,T., Mattheijssens,M., Van den Broeck,M.,Cuijt,I.,Vennekens,K., De Deyn,P.P, Kumar-Singh,S., Van Broeckhoven,C. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21, Nature, 442(7105):920-924 (2006) • van der Zee,J., Rademakers,R., Engelborghs,S., Gijselinck,I., Bogaerts,V., Vandenberghe,R., Santens,P., Caekebeke,J., De Pooter,T., Peeters,K., Lübke,U., Van den Broeck,M., Martin,J-J., Cruts,M., De Deyn,P.P., Van Broeckhoven,C., Dermaut,B.: A Belgian Ancestral Haplotype Harbors a Highly Prevalent mutation for 17q21-Linked Tau-negative FTLD. Brain 129(4): 841-852 (2006) • Pirici,D., van der Zee,J., Vandenberghe,R., Rademakers,R., Dermaut,B., Cruts,M., Vennekens,K., Cuijt,I., Lübke,U., Ceuterick,C., Martin,J-J., Van Broeckhoven,C., Kumar-Singh,S.: Characterization of ubiquitinated intraneural inclusions in a novel Belgian FTLD family. Journal of Neuropathology &Experimental Neurology 65(3): 289-301 (2006)

  38. 0 8 1 2 3 4 5 6 7 9 10 11 12 UTR mRNA UTR P G F B A C D E 593 codons FTDU-17 gene is progranulin • PGRN is located at 17q21.32, 1.7 Mb centromeric of MAPT • Growth modulatory activity • Role in several physiological and pathological processes (development, wound repair, inflammation and tumorigenesis) • Cysteine-rich polypeptide • 7.5 x 12-cysteine granulin motif • Function in brain? gDNA Baker et al. and Cruts et al. Nature 2006

  39. Laboratory for Ultrastructural neuropathology & Biobank

  40. IBB BIOBANK Co-ordinator: PP De Deyn Brain Neuromuscular specimens / skin Cerebrospinal fluid Blood - plasma - serum DNA, Cell cultures Human & animal Task Forces TF 3 TF 1 TF 2 CNS Neurodegenerative Disorders (dementia/park) Responsibles: C. Van Broeckhoven & PP. De Deyn S. Engelborghs S. Kumar-Singh Consultant: J.J. Martin (LNG, LNB) Neuromuscular Disorders Responsible: C. Ceuterick P. De Jonghe/ V. Timmerman K. Claeys, L. Heytens Consultant: J.J. Martin (NMRC UZA, LUN) Prion Diseases Responsible: P. Cras (Lab. of Neurobiology)

  41. Impact factors of IBB publications in 2009

More Related